- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00003387
Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery
Concurrent Carboplatin, Paclitaxel, and Radiation Therapy Versus Induction Carboplatin and Paclitaxel Followed by Concurrent Carboplatin, Paclitaxel and Radiation Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer: A Phase III Trial
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether giving chemotherapy before combined chemotherapy and radiation therapy is more effective than combined chemotherapy and radiation therapy alone in treating patients with non-small cell lung cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of carboplatin and paclitaxel followed by radiation therapy and chemotherapy with radiation therapy and chemotherapy alone in treating patients with stage III non-small cell lung cancer that cannot be removed during surgery.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
OBJECTIVES: I. Compare the effects of concurrent chemoradiotherapy utilizing carboplatin and paclitaxel with or without prior induction chemotherapy on overall response rate, disease-free survival, and overall survival in patients with unresectable stage III non-small cell lung cancer. II. Compare the effects of these treatments on locoregional vs distant failure in these patients. III. Compare the toxicity of these treatments in these patients.
OUTLINE: This is a randomized study. Patients are stratified by measurable vs evaluable disease. Patients are randomized to 1 of 2 treatment arms: Arm I (immediate concurrent chemoradiotherapy): Patients receive IV paclitaxel over 1 hour followed by IV carboplatin over 30 minutes on day 1, and radiation therapy to the chest 5 times a week beginning on day 1. Treatment repeats weekly for a total of 7 courses. Arm II (induction chemotherapy followed by delayed concurrent chemoradiotherapy): Patients receive IV paclitaxel over 3 hours followed by IV carboplatin over 30 minutes; treatment repeats every 3 weeks for 2 courses. Patients then receive 7 courses of concurrent chemoradiotherapy as in Arm I. Total treatment time is 13 weeks. Patients are followed every 2 months for 2 years, then every 4 months for the next 2 years, then annually thereafter.
PROJECTED ACCRUAL: A total of 360 patients will be accrued for this study within 3 years.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35233-1996
- Veterans Affairs Medical Center - Birmingham
-
-
California
-
La Jolla, California, Förenta staterna, 92093-0658
- University of California San Diego Cancer Center
-
San Francisco, California, Förenta staterna, 94121
- Veterans Affairs Medical Center - San Francisco
-
San Francisco, California, Förenta staterna, 94143-0128
- UCSF Cancer Center and Cancer Research Institute
-
-
Delaware
-
Wilmington, Delaware, Förenta staterna, 19899
- CCOP - Christiana Care Health Services
-
-
District of Columbia
-
Washington, District of Columbia, Förenta staterna, 20307-5000
- Walter Reed Army Medical Center
-
Washington, District of Columbia, Förenta staterna, 20060
- Howard University Cancer Center
-
-
Florida
-
Miami Beach, Florida, Förenta staterna, 33140
- CCOP - Mount Sinai Medical Center
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60612
- Veterans Affairs Medical Center - Chicago (Westside Hospital)
-
Chicago, Illinois, Förenta staterna, 60637-1470
- University of Chicago Cancer Research Center
-
Chicago, Illinois, Förenta staterna, 60612
- University of Illinois at Chicago Health Sciences Center
-
-
Iowa
-
Bettendorf, Iowa, Förenta staterna, 52722
- Hematology Oncology Associates of the Quad Cities
-
Iowa City, Iowa, Förenta staterna, 52242-1009
- Holden Comprehensive Cancer Center at the University of Iowa
-
-
Maine
-
Togus, Maine, Förenta staterna, 04330
- Veterans Affairs Medical Center - Togus
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21201
- Marlene & Stewart Greenebaum Cancer Center, University of Maryland
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02115
- Dana-Farber Cancer Institute
-
Worcester, Massachusetts, Förenta staterna, 01655
- University of Massachusetts Memorial Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, Förenta staterna, 55417
- Veterans Affairs Medical Center - Minneapolis
-
-
Missouri
-
Columbia, Missouri, Förenta staterna, 65201
- Veterans Affairs Medical Center - Columbia (Truman Memorial)
-
Columbia, Missouri, Förenta staterna, 65203
- Ellis Fischel Cancer Center - Columbia
-
Saint Louis, Missouri, Förenta staterna, 63110
- Barnes-Jewish Hospital
-
-
Nebraska
-
Omaha, Nebraska, Förenta staterna, 68198-3330
- University of Nebraska Medical Center
-
-
Nevada
-
Las Vegas, Nevada, Förenta staterna, 89106
- CCOP - Southern Nevada Cancer Research Foundation
-
-
New Hampshire
-
Lebanon, New Hampshire, Förenta staterna, 03756-0002
- Norris Cotton Cancer Center
-
-
New Jersey
-
Camden, New Jersey, Förenta staterna, 08103
- Cooper Cancer Institute
-
-
New York
-
Buffalo, New York, Förenta staterna, 14263-0001
- Roswell Park Cancer Institute
-
Buffalo, New York, Förenta staterna, 14215
- Veterans Affairs Medical Center - Buffalo
-
Manhasset, New York, Förenta staterna, 11030
- CCOP - North Shore University Hospital
-
Manhasset, New York, Förenta staterna, 11030
- North Shore University Hospital
-
New York, New York, Förenta staterna, 10021
- Memorial Sloan-Kettering Cancer Center
-
New York, New York, Förenta staterna, 10021
- New York Presbyterian Hospital - Cornell Campus
-
New York, New York, Förenta staterna, 10029
- Mount Sinai Medical Center, NY
-
Syracuse, New York, Förenta staterna, 13210
- State University of New York - Upstate Medical University
-
Syracuse, New York, Förenta staterna, 13210
- Veterans Affairs Medical Center - Syracuse
-
Syracuse, New York, Förenta staterna, 13217
- CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.
-
-
North Carolina
-
Chapel Hill, North Carolina, Förenta staterna, 27599-7295
- Lineberger Comprehensive Cancer Center, UNC
-
Durham, North Carolina, Förenta staterna, 27705
- Veterans Affairs Medical Center - Durham
-
Durham, North Carolina, Förenta staterna, 27710
- Duke Comprehensive Cancer Center
-
Winston-Salem, North Carolina, Förenta staterna, 27104-4241
- CCOP - Southeast Cancer Control Consortium
-
Winston-Salem, North Carolina, Förenta staterna, 27157-1082
- Comprehensive Cancer Center at Wake Forest University
-
-
Rhode Island
-
Providence, Rhode Island, Förenta staterna, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Charleston, South Carolina, Förenta staterna, 29425-0721
- Medical University of South Carolina
-
-
Tennessee
-
Memphis, Tennessee, Förenta staterna, 38103
- University of Tennessee, Memphis Cancer Center
-
Memphis, Tennessee, Förenta staterna, 38104
- Veterans Affairs Medical Center - Memphis
-
-
Vermont
-
White River Junction, Vermont, Förenta staterna, 05009
- Veterans Affairs Medical Center - White River Junction
-
-
Virginia
-
Richmond, Virginia, Förenta staterna, 23298-0037
- MBCCOP - Massey Cancer Center
-
Richmond, Virginia, Förenta staterna, 23249
- Veterans Affairs Medical Center - Richmond
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed non-small cell lung cancer, including: Squamous cell carcinoma Adenocarcinoma (including bronchoalveolar cell) Large cell anaplastic carcinoma (including giant and clear cell carcinomas) Inoperable or unresectable stage IIIA or IIIB disease of the following stage groupings: T1 N2 M0 or T2 N2 M0 T3 N2 M0 and T4 N0-2 M0 eligible if staging is based on closeness to the carina or invasion of the mediastinum or chest wall Patients with contralateral mediastinal disease (N3) or tumors adjacent to but not invading a vertebral body are eligible if all gross disease can be encompassed in the study radiation boost field Patients with a transudate, cytologically negative, nonbloody pleural effusion are eligible if the tumor can be encompassed within a reasonable field of radiotherapy Measurable or evaluable disease
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: CALBG 0-1 Life expectancy: Not specified Hematopoietic: Platelet count at least 100,000/mm3 Absolute granulocyte count at least 1,500/mm3 Hepatic: Bilirubin less than 1.5 mg/dL AST less than 2 times upper limit of normal Renal: Creatinine clearance at least 20 mL/min Other: Not pregnant or nursing Effective contraception required of fertile patients No active second malignancy except nonmelanomatous skin cancer
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy No other concurrent chemotherapy Endocrine therapy: No concurrent hormones except for steroids administered for adrenal failure or septic shock, or hormones administered for non-disease-related conditions (e.g., insulin for diabetes) Glucocorticosteroids permitted as antiemetics Radiotherapy: No prior radiotherapy Surgery: At least 2 weeks since exploratory thoracotomy
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Chemo + radiation
|
|
|
Experimentell: Induction chemo + chemo & radiation
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
total överlevnad
Tidsram: Upp till 5 år
|
Upp till 5 år
|
|
den totala svarsfrekvensen
Tidsram: Upp till 5 år
|
Upp till 5 år
|
|
sjukdomsfri överlevnad
Tidsram: Upp till 5 år
|
Upp till 5 år
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Studiestol: Everett E. Vokes, MD, University of Chicago
Publikationer och användbara länkar
Allmänna publikationer
- Stinchcombe TE, Hodgson L, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Niell HB, Atkins JN, Akerley W, Green MR, Vokes EE; Cancer and Leukemia Group B. Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2009 Sep;4(9):1117-25. doi: 10.1097/JTO.0b013e3181b27b33.
- Vokes EE, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, Atkins JN, Watson DM, Akerley W, Green MR; Cancer and Leukemia Group B. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007 May 1;25(13):1698-704. doi: 10.1200/JCO.2006.07.3569. Epub 2007 Apr 2.
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Luftvägssjukdomar
- Neoplasmer
- Lungsjukdomar
- Neoplasmer efter plats
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Karcinom, bronkogent
- Bronkiella neoplasmer
- Lungneoplasmer
- Karcinom, icke-småcellig lunga
- Molekylära mekanismer för farmakologisk verkan
- Antineoplastiska medel
- Tubulin modulatorer
- Antimitotiska medel
- Mitosmodulatorer
- Antineoplastiska medel, fytogena
- Karboplatin
- Paklitaxel
Andra studie-ID-nummer
- CALGB-39801
- U10CA031946 (U.S.S. NIH-anslag/kontrakt)
- CLB-39801
- CDR0000066383 (Registeridentifierare: NCI Physician Data Query)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .